Rapamycin has stronger evidence for extending lifespan in animals, while metformin has a more established safety record in humans. At Longevity Benchmark, one of the most common mistakes we see is treating them as interchangeable. They aren't. Neither drug is approved to slow aging, so the debate over rapamycin versus metformin for longevity remains a research question, not a prescribing decision.
The Verdict
Rapamycin vs Metformin for Longevity Compared on Six Criteria
Rapamycin and metformin sit at opposite ends of the evidence a reader cares about. Rapamycin has the animal lifespan result. Metformin has the human track record.
| Criterion | Rapamycin | Metformin |
|---|---|---|
| Animal lifespan evidence | Extended median and 90th percentile lifespan in genetically heterogeneous mice, at three laboratories, including when first fed at 600 days of age | No lifespan benefit on its own in the same program. Males gained 7% in median lifespan, a difference the reported P value of 0.35 places inside the range of chance |
| Human aging evidence | One 48-week randomized trial in healthy adults, which missed its primary outcome. No completed trial with a disease or mortality endpoint | The TAME trial was designed to answer this and has not reported. Decades of outcome data exist in type 2 diabetes. None of it is about aging |
| Mechanism | Inhibits mTOR (mechanistic target of rapamycin), the pathway that tells a cell to grow when nutrients are plentiful, which shifts cells toward recycling their own damaged parts | Activates AMPK (AMP-activated protein kinase) and inhibits complex I of the mitochondrial electron transport chain, which cuts glucose output from the liver |
| Approved use in the US | Preventing rejection in kidney transplant recipients, and treating lymphangioleiomyomatosis (LAM), a rare lung disease | Type 2 diabetes, alongside diet and exercise |
| Cost and access | Prescription only. Off-label for aging, usually paid in cash, and priced well above metformin | Prescription only. Off-label for aging, and among the cheapest generics a US pharmacy stocks |
| Main side effects | Mouth ulcers, raised blood lipids, slower wound healing, and infection risk from immune suppression | Diarrhea and nausea in the first weeks, lower vitamin B12 over years, and rare lactic acidosis |
| Verdict | The strongest animal lifespan result in aging biology, and the thinner human evidence of the two | The stronger human safety record, and no lifespan signal when given on its own |
A drug with a replicated lifespan result in mammals and no human outcome trial is one kind of bet. A drug taken by millions of people for decades with no lifespan result to its name is another. Decide which of those two gaps you are more willing to live with.
What the NIA Interventions Testing Program Found
The Interventions Testing Program is the reference standard for animal lifespan claims, because it was built to break the results smaller labs produce. Compounds run in parallel at three independent laboratories, in genetically heterogeneous mice rather than one inbred strain, so a result cannot be an artifact of a single genetic background. Every outcome gets published, including the failures.
Rapamycin cleared that bar more than once:
- Fed from 600 days of age, roughly late middle age for a mouse, rapamycin raised mean lifespan by about 9% in males and 13% in females. It raised 90th percentile survival too. That result was published in Nature in 2009, and it is the reason rapamycin dominates this field.
- A later Aging Cell report showed the effect scales with dose. A threefold higher dose started at 9 months of age raised median survival by 23% in males and 26% in females.
- The effect held across sexes, doses and sites, which is the pattern almost every other candidate compound fails to produce.
Metformin did not clear it. In the program's 2016 Aging Cell report, metformin at 0.1% of the diet produced a 7% median lifespan gain in males. The reported P value of 0.35 puts that difference inside the range of chance, and females showed nothing at all.
The same report found something more useful for anyone weighing the pair. Metformin combined with rapamycin raised median survival by 23% in both sexes, beyond what earlier rapamycin-only cohorts had reached. One mouse combination result is not a human protocol, and it is why the two drugs keep being discussed together.
Mice are the limit of this evidence. No ITP compound has been shown to extend human life, and the program measures lifespan rather than the diseases people want postponed.
Why the Human Evidence Runs the Other Way
Metformin has the human record rapamycin lacks, and none of it was gathered to answer a question about aging. Metformin is the standard first-line drug for type 2 diabetes and one of the most widely prescribed medicines in the world. Its side effects at scale are documented in a way rapamycin's never will be from longevity clinics.
The anti-aging hypothesis came from an observation inside that diabetes data. A 2014 analysis in Diabetes, Obesity and Metabolism compared UK primary-care patients started on metformin with matched people who did not have diabetes. The metformin group survived slightly longer than those controls. The analysis is observational, and its authors treated the finding as hypothesis-generating rather than settled.
The TAME trial was designed to test that hypothesis properly. Targeting Aging with Metformin (TAME) is a randomized, double-blind, placebo-controlled design in older adults without diabetes, backed by the American Federation for Aging Research (AFAR). Its composite primary endpoint counts the first occurrence of heart attack, stroke, heart failure, cancer, dementia or death, which tests aging broadly instead of testing one disease.
TAME has not reported results. Money has been the obstacle rather than the science, because metformin is a generic that no company earns a return on. AFAR's own page for the trial carries the current funding and enrollment status.
Rapamycin has no equivalent trial. The largest randomized human study aimed at aging is PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity), run by AgelessRx and published in Aging in 2025. It compared weekly 5 mg or 10 mg compounded rapamycin against placebo for 48 weeks in healthy adults aged 50 to 85. It had 114 completers.
The primary outcome was visceral fat measured by dual-energy X-ray absorptiometry (DXA), and rapamycin did not move it. Adverse events were similar across the three groups, with more gastrointestinal complaints on rapamycin. PEARL is a useful one-year safety read rather than evidence that rapamycin slows human aging.
Metformin Blunts Part of the Training Response
Metformin reduced the adaptation to exercise training in two randomized trials in older adults. In a 2019 Aging Cell trial, adding metformin to supervised aerobic training attenuated the training-driven improvements in whole-body insulin sensitivity, cardiorespiratory fitness and skeletal muscle mitochondrial respiration.
The resistance-training result points the same way. In the MASTERS trial, 94 older adults took 1,700 mg of metformin daily or placebo through 14 weeks of progressive resistance training. The placebo group gained more lean body mass and more thigh muscle than the metformin group.
Two conclusions follow, and they point different ways for different readers. If you take metformin for type 2 diabetes, keep taking it and keep training, because both groups in both trials still improved and uncontrolled blood sugar is the larger problem.
If you are healthy and considering metformin as an aging drug while building a training habit, metformin may work against the adaptation you are training for. Our Zone 2 cardio guide and the case for creatine for longevity both rest on the human adaptation data that metformin partly attenuates.
mTOR Inhibition vs AMPK Activation
The two drugs pull different levers, and the difference explains why one produced a lifespan result and the other did not. Rapamycin binds a protein called FKBP12 and through it inhibits mTOR complex 1, the sensor that tells a cell to build when nutrients are abundant. Damping that signal pushes cells toward autophagy, the process of breaking down and recycling their own damaged parts, which is the direction prolonged fasting also pushes.
Metformin works on fuel supply rather than on the growth pathway. It inhibits complex I of the mitochondrial electron transport chain and activates AMPK, the enzyme cells use to sense low energy. The practical result is less glucose released by the liver and better insulin sensitivity. That lowers HbA1c (hemoglobin A1c) in type 2 diabetes and does little in people whose glucose is already normal.
Both get called caloric restriction mimetics. The label names a hypothesis about mechanism, and only rapamycin has turned that hypothesis into a lifespan result.
Access and Monitoring for Rapamycin and Metformin
Both are prescription-only in the United States, and neither carries an FDA indication for aging, so every longevity use of either is off-label. Off-label prescribing is legal, and it means a clinician has to agree the use makes sense for you.
- Rapamycin. Sold as Rapamune (sirolimus) and approved to prevent rejection in kidney transplant recipients and to treat lymphangioleiomyomatosis. Its label carries a boxed warning covering immune suppression, infection and lymphoma risk at transplant doses. Longevity dosing is weekly and far lower, which is why the transplant safety record does not transfer cleanly in either direction. Expect to pay cash, and expect lipids, blood counts and glucose to be checked.
- Metformin. Sold as Glucophage (metformin hydrochloride) and approved for type 2 diabetes alongside diet and exercise. Its label carries a boxed warning for lactic acidosis and restricts use in severe kidney impairment. It is among the cheapest generics a US pharmacy stocks. Long-term use lowers vitamin B12, and the label advises an annual blood count, plus a B12 level every two to three years for anyone prone to deficiency.
Cost is the smaller obstacle for metformin and the larger one for rapamycin, since an off-label longevity prescription is rarely covered by insurance. Ask the prescribing clinic for the cash price of the prescription and the monitoring blood work together, because the tests are the part people forget to budget for.
When Rapamycin vs Metformin for Longevity Is the Relevant Question
Rapamycin and metformin are the right question for different readers, and for most people neither one is. Three cases separate cleanly.
- Rapamycin is the relevant question if you have read the ITP results and want to know whether the strongest animal result in aging biology transfers to humans. The answer today is that nobody knows, and the human evidence stops at one year of safety data in 114 people.
- Metformin is the relevant question if you already have prediabetes or type 2 diabetes. That is a blood sugar decision with a real evidence base rather than a longevity decision, and our prediabetes reversal guide covers where diet and training sit against medication.
- Neither is the relevant question if you are chasing a lower biological age reading. Neither drug's human data has been shown to move an epigenetic clock in a way that predicts outcomes. The levers that do have human evidence are covered in how to lower biological age.
For the longer treatment of one side of this comparison, our page on rapamycin for longevity goes further into dosing conventions and the monitoring that off-label use requires.
Who Should Not Take Rapamycin or Metformin
Anyone under 50 with normal glucose, normal lipids and no training habit should skip this comparison. The return on either drug in that group is unmeasured, and the return on twelve weeks of consistent aerobic and resistance work shows up on a blood panel. Build that first, then reopen the question.
Anyone training for muscle should treat metformin as a cost rather than a bonus, on the strength of the MASTERS result. Anyone facing surgery, healing a wound, or living with a suppressed immune system should not take rapamycin. Slower wound healing and infection risk are the effects its label documents most clearly. Anyone with reduced kidney function needs the metformin question answered by the clinician who tracks their kidney numbers.
What Would Change Our Answer on Rapamycin vs Metformin for Longevity
Two specific results would flip this verdict, and both are identifiable in advance. TAME reporting a positive composite endpoint would move metformin from a hypothesis with good safety data to the first drug shown to delay age-related disease in people. A completed randomized rapamycin trial in older adults with a hard endpoint, such as infections, fractures, hospital admissions or mortality, would do the same for rapamycin. PEARL's body-composition endpoint was never going to.
Until one of those results lands, rapamycin vs metformin for longevity stays an open research question rather than a shopping decision. Book the fasting glucose, HbA1c and lipid panel that would tell you whether you have a metabolic problem worth treating first.
Frequently Asked Questions
Is rapamycin a longevity drug?
Rapamycin is a longevity drug in mice and an open question in people. It extended median and maximum lifespan in genetically heterogeneous mice in the National Institute on Aging Interventions Testing Program, at three laboratories. Feeding that began at 600 days of age still worked. Nothing comparable has been shown in humans. The largest randomized human trial to date ran 48 weeks, had 114 completers, and missed its primary outcome. Rapamycin is approved only for transplant rejection and for lymphangioleiomyomatosis, so every longevity use is off-label.
Is metformin good for anti aging?
Metformin has the best safety record of any candidate anti-aging drug and the weakest lifespan evidence. It did not extend lifespan on its own in the Interventions Testing Program, the same mouse program where rapamycin succeeded. The human case rests on observational work, most famously a 2014 UK primary-care analysis in which people started on metformin for type 2 diabetes outlived matched people without diabetes. The TAME trial was designed to test that properly and has not reported. Until it does, metformin for aging is untested in people who have no blood sugar problem.
Which has better evidence, rapamycin or metformin?
It depends on which species you accept as evidence. Rapamycin has the better animal lifespan data by a wide margin, replicated across sites and doses and reproduced when started late in life. Metformin has the better human data, and that data is about treating type 2 diabetes rather than about slowing aging. Neither has a completed randomized trial showing it delays age-related disease in people. Anyone who calls one of them proven is describing mice or describing diabetes.
Can you take rapamycin and metformin together?
The combination has been tested in mice. No trial has tested it in people. In the Interventions Testing Program, metformin at 0.1% of the diet combined with rapamycin raised median survival by 23% in both sexes. The investigators noted that was beyond what earlier rapamycin-only cohorts reached. That is one mouse result, and it says nothing about safety or benefit in a person taking both off-label. Two prescription drugs with overlapping metabolic effects also make side effects harder to attribute when something goes wrong. Anyone considering it needs a clinician who will monitor lipids, glucose, kidney function and blood counts.
Why did metformin fail in the mouse lifespan program if it works in diabetes?
Lowering blood glucose in an animal with normal glucose leaves little to fix. Metformin cuts liver glucose output and improves insulin sensitivity, and most of its documented benefit comes from correcting a metabolic problem that already exists. The mice in the Interventions Testing Program were healthy and genetically diverse rather than diabetic. That gap is the same reason the anti-aging case in humans is unresolved, since nearly all of the outcome data comes from people who needed metformin for their blood sugar.
Does metformin cancel out exercise?
Metformin blunts part of the adaptation to training in older adults, and it does not cancel exercise. In a 2019 Aging Cell trial, adding metformin to aerobic training in older adults reduced the training-driven gains in insulin sensitivity, cardiorespiratory fitness and muscle mitochondrial respiration. In the MASTERS resistance-training trial, the placebo group gained more lean mass and more thigh muscle than the metformin group over 14 weeks. Both groups still improved. If you have diabetes and take metformin, keep training and keep taking it.
How do people get rapamycin for longevity?
They get an off-label prescription from a clinician willing to write one, and they usually pay cash. Off-label prescribing is legal in the United States and generic sirolimus is available, but no insurer covers it for aging and no professional body endorses the use. Longevity dosing is intermittent and far below transplant doses, which is why the transplant safety record does not transfer cleanly in either direction. Ask what monitoring comes with the prescription before you fill it, because lipids, blood counts and glucose all need watching.
What is the TAME trial and has it started?
TAME stands for Targeting Aging with Metformin, a randomized, double-blind, placebo-controlled trial designed to test whether metformin delays the onset of age-related disease in older adults who do not have diabetes. Its composite primary endpoint counts the first occurrence of heart attack, stroke, heart failure, cancer, dementia or death, rather than any single disease. TAME has not reported results, and funding has been the obstacle, because metformin is a generic no company profits from. The American Federation for Aging Research page for TAME posts its recruitment status.